Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities

Holly Hagan, Mary H. Latka, Jennifer V. Campbell, Elizabeth T. Golub, Richard S. Garfein, David A. Thomas, Farzana Kapadia, Steffanie A. Strathdee

Research output: Contribution to journalArticle

Abstract

Among 404 injection drug users aged 18-35 who tested positive for hepatitis C virus (HCV) RNA, 96% had conditions that are potentially unwarranted contraindications for HCV treatment (e.g., problem drinking, moderate-to-severe depression, and recent drug injection). Restrictive eligibility criteria may deny treatment to a large proportion of patients who could benefit from it.

Original languageEnglish (US)
Pages (from-to)669-672
Number of pages4
JournalClinical Infectious Diseases
Volume42
Issue number5
DOIs
StatePublished - Mar 1 2006

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities'. Together they form a unique fingerprint.

  • Cite this

    Hagan, H., Latka, M. H., Campbell, J. V., Golub, E. T., Garfein, R. S., Thomas, D. A., Kapadia, F., & Strathdee, S. A. (2006). Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clinical Infectious Diseases, 42(5), 669-672. https://doi.org/10.1086/499951